Copenhagen, Hovedstaden, Denmark The leading representative office of defined VC is situated in the Copenhagen. The fund was located in Europe if to be more exact in Denmark.
Among the various public portfolio startups of the fund, we may underline F2G, Anergis, OxThera Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Denmark. Among the most successful fund investment fields, there are Electronics, Medical. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 3 of the founder, the chance for it to get the investment is meager.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. Comparing to the other companies, this Sunstone Life Science Ventures performs on 2 percentage points less the average number of lead investments. The increased amount of exits for fund were in 2014.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Sunstone Life Science Ventures, startups are often financed by Novo Seeds, Novo Holdings, Novartis Venture Fund. The meaningful sponsors for the fund in investment in the same round are Novo Holdings, Forbion Capital Partners, Omega Funds. In the next rounds fund is usually obtained by Novo Holdings, Atlas Venture, Aescap Venture.
The overall number of key employees were 6.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Bluefield Investments | England, London, United Kingdom |
| Chongqing Gaoxin Jishu Chanye Kaifaqu Chuangxin Fuwu Zhongxin | China, Chongqing, Chongqing Shi |
| Divergent Ventures | Seattle, United States, Washington |
| Fuyu (Shanghai) Investment Management | - |
| Harbour | China, Shanghai |
| Honest Ventures | - |
| ICON Continuity Fund | - |
| KDB Bank | - |
| Launch TN Impact Fund | - |
| Newsion Venture Capital | Beijing, Beijing, China |
| Ontario | Canada, Ontario, Toronto |
| PeopleSoft | California, Pleasanton, United States |
| Ping An Bank | China, Guangdong Province, Huizhou |
| Polymath Capital | California, San Francisco, United States |
| Shanghai Decun Touzi Youxian Gongsi | China, Shanghai |
| Skandia.se | Stockholm, Stockholm County, Sweden |
| Tiger Holding | Norway, Oslo |
| UCAL Fuel Systems | Chennai, India, Tamil Nadu |
| Unicom Venture Capital | Beijing, Beijing, China |
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Resalis Therapeutics | $11M | 04 Jan 2024 | Torino, Piemonte, Italy | ||
Kynexis | $67M | 07 Nov 2023 | - | ||
DiogenX | $39M | 10 May 2023 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Teitur Trophics | $33M | 14 Mar 2023 | Aarhus, Midtjylland, Denmark | ||
Rewind Therapeutics | 25 Jan 2023 | - | |||
Minervax | $25M | 15 Dec 2022 | Denmark, Capital Region of Denmark, Denmark | ||
TargED Biopharmaceuticals | $46M | 19 Feb 2022 | Utrecht, Utrecht, The Netherlands | ||
Step Pharma | $41M | 24 Mar 2021 | Paris, Ile-de-France, France | ||
IO Biotech | $149M | 13 Jan 2021 | Capital Region of Denmark |
– Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, today announced the successful closing of a EUR35 million Series B financing.
– New investors Hadean Ventures and Sunstone Life Science Ventures co-led the round, joining existing investors Kurma Partners, Pontifax and Bpifrance, which reinvested through its Innovative Biotherapies and Rare Diseases fund and InnoBio 2 fund.
– As part of the financing, Jacob L Moresco from Sunstone Life Science Ventures and Walter Stockinger from Hadean Ventures will join the Step Pharma Board of Directors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Resalis Therapeutics | $11M | 04 Jan 2024 | Torino, Piemonte, Italy | ||
Kynexis | $67M | 07 Nov 2023 | - | ||
DiogenX | $39M | 10 May 2023 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Teitur Trophics | $33M | 14 Mar 2023 | Aarhus, Midtjylland, Denmark | ||
Rewind Therapeutics | 25 Jan 2023 | - | |||
Minervax | $25M | 15 Dec 2022 | Denmark, Capital Region of Denmark, Denmark | ||
TargED Biopharmaceuticals | $46M | 19 Feb 2022 | Utrecht, Utrecht, The Netherlands | ||
Step Pharma | $41M | 24 Mar 2021 | Paris, Ile-de-France, France | ||
IO Biotech | $149M | 13 Jan 2021 | Capital Region of Denmark |
